Key Points
-
Transforming growth factor-β (TGF-β) inhibits the differentiation of both CD4+ and CD8+ naive T cells into effectors. This effect is not dependent on inhibition of proliferation.
-
TGF-β blocks T helper (TH)2 development by inhibiting expression of Gata-3 (a master TH2 transcriptional activator).
-
Similarly, TGF-β might block TH1 development through inhibition of a master TH1 transcriptional activator; a candidate is T-bet (T-box expressed in T cells).
-
Early interferon-γ (IFN-γ) production by differentiating TH1 cells can protect from the inhibitory effects of TGF-β. Fully differentiated TH1 cells do not express the IFN-γ receptor are so are resistant to the protective effects of IFN-γ.
-
Fully differentiated TH2 cells are resistant to the inhibitory effects of TGF-β, but the mechanism has not been elucidated.
-
T cells activated in vitro in the presence of TGF-β resemble central memory T cells in that they retain the capacity to produce interleukin-2 (IL-2) and can differentiate to TH1 or TH2 effector cells when restimulated.
-
Blocking TGF-β signalling in T cells by using transgenic approaches leads to spontaneous T-cell activation and inflammation, indicating that TGF-β signalling in T cells is essential for T-cell homeostasis.
-
The role for TGF-β in controlling T-cell homeostasis seems to be in preventing inappropriate responses to certain self- or environmental antigens, rather than control of normal T-cell responses to low-avidity self-ligands that constitute survival signals.
-
When TGF-β signalling is blocked in T cells, inflammation is most severe at mucosal sites where exposure to environmental antigens is highest (gut and lung). Dysregulated responses to the normal gut flora have been implicated in the pathogenesis of inflammatory bowel disease.
-
Mucosal T cells from patients with inflammatory bowel disease (IBD) express high levels of Smad7, an inhibitor of TGF-β signalling, implying dysregulated TGF-β signalling might have a role in the pathogenesis of IBD.
-
A cell-surface form of TGF-β might be important for CD4+CD25+ regulatory T-cell function.
-
TGF-β released directly by apoptotic cells, or by antigen-presenting cells that have ingested apoptotic cells, might prevent T-cell responses to self-antigens.
-
TGF-β might also inhibit T cells indirectly through its inhibitory effects on antigen-presenting cells.
-
TGF-β production is associated with many tumours and might normally suppress tumour-specific T-cell responses, as blocking TGF-β signals in T cells in mice leads to the generation of potent CD8+ T-cell responses and tumour rejection.
Abstract
Strict control of T-cell homeostasis is required to permit normal immune responses and prevent undesirable self-targeted responses. Transforming growth factor-β (TGF-β) has been shown to have an essential role in that regulation. Owing to its broad expression, and inhibitory effects on multiple cell types of the immune system, TGF-β regulation is complex. Through advances in cell-specific targeting of TGF-β signalling in vivo, the role of TGF-β in T-cell regulation has become clearer. Recent in vitrostudies provide a better understanding of how TGF-β regulates T-cell homeostasis, through multiple mechanisms involving numerous cell types.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693–699 (1992).
Kulkarni, A. B. et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770–774 (1993).
Kaartinen, V. et al. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial–mesenchymal interaction. Nature Genet. 11, 415–421 (1995).
Proetzel, G. et al. Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet. 11, 409–414 (1995).
Sanford, L. P. et al. TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 124, 2659–2670 (1997).
Schluesener, H., Jung, S. & Salvetti, M. Susceptibility and resistance of human autoimmune T cell activation to the immunoregulatory effects of transforming growth factor (TGF) β1, β2, and β1.2. J. Neuroimmunol. 28, 271–276 (1990).
Stoeck, M. et al. Comparison of the immunosuppressive properties of milk growth factor and transforming growth factors β1 and β2. J. Immunol. 143, 3258–3265 (1989).
Kehrl, J. H. et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163, 1037–1050 (1986).First demonstration of the important role of TGF-β in T-cell regulation.
Brabletz, T. et al. Transforming growth factor β and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol. Cell. Biol. 13, 1155–1162 (1993).
Hannon, G. J. & Beach, D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257–261 (1994).
Datto, M. B. et al. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl Acad. Sci. USA 92, 5545–5549 (1995).
Polyak, K. et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8, 9–22 (1994).
Coffey, R. J. Jr. et al. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor β. Mol. Cell. Biol. 8, 3088–3093 (1988).
Sad, S. & Mosmann, T. R. Single IL-2-secreting precursor CD4 T cell can develop into either TH1 or TH2 cytokine secretion phenotype. J. Immunol. 153, 3514–3522 (1994).
Swain, S. L., Huston, G., Tonkonogy, S. & Weinberg, A. Transforming growth factor-β and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 147, 2991–3000 (1991).
Ranges, G. E., Figari, I. S., Espevik, T. & Palladino, M. A. Jr. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166, 991–998 (1987).
Hoehn, P. et al. Opposing effects of TGF-β2 on the TH1 cell development of naive CD4+ T cells isolated from different mouse strains. J. Immunol. 155, 3788–3793 (1995).
Lingnau, K. et al. IL-4 in combination with TGF-β favors an alternative pathway of TH1 development independent of IL-12. J. Immunol. 161, 4709–4718 (1998).
Hayashi, H. et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 89, 1165–1173 (1997).
Nakao, A. et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 389, 631–635 (1997).
Ulloa, L., Doody, J. & Massague, J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature 397, 710–713 (1999).
Tau, G. Z. et al. Interferon-γ signaling alters the function of T helper type 1 cells. J. Exp. Med. 192, 977–986 (2000).
Kitani, A. et al. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid: TGF-β1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor β2 chain downregulation. J. Exp. Med. 192, 41–52 (2000).
Ludviksson, B. R., Seegers, D., Resnick, A. S. & Strober, W. The effect of TGF-β1 on immune responses of naive versus memory CD4+ TH1/TH2 T cells. Eur. J. Immunol. 30, 2101–2111 (2000).
Gorelik, L., Fields, P. E. & Flavell, R. A. Cutting edge: TGF-β inhibits TH type 2 development through inhibition of GATA-3 expression. J. Immunol. 165, 4773–4777 (2000).
Heath, V. L., Murphy, E. E., Crain, C., Tomlinson, M. G. & O'Garra, A. TGF-β1 down-regulates TH2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur. J. Immunol. 30, 2639–2649 (2000).
Zheng, W. & Flavell, R. A. The transcription factor GATA-3 is necessary and sufficient for TH2 cytokine gene expression in CD4 T cells. Cell 89, 587–596 (1997).Identification of Gata-3 as a crucial factor in T H 2 differentiation.
Gorham, J. D., Guler, M. L., Fenoglio, D., Gubler, U. & Murphy, K. M. Low dose TGF-β attenuates IL-12 responsiveness in murine TH cells. J. Immunol. 161, 1664–1670 (1998).
Szabo, S. J. et al. A novel transcription factor, T-bet, directs TH1 lineage commitment. Cell 100, 655–669 (2000).Cloning of a new T-box protein, T-bet, and demonstration of the important role it has in IFN-γ production.
Mullen, A. C. et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292, 1907–1910 (2001).Investigated the relative input of T-bet and IL-12 signalling in T H 1 development.
Xanthos, J. B., Kofron, M., Wylie, C. & Heasman, J. Maternal VegT is the initiator of a molecular network specifying endoderm in Xenopus laevis. Development 128, 167–180 (2001).
Weber, H., Symes, C. E., Walmsley, M. E., Rodaway, A. R. & Patient, R. K. A role for GATA5 in Xenopus endoderm specification. Development 127, 4345–4360 (2000).
Nikaido, M., Tada, M., Takeda, H., Kuroiwa, A. & Ueno, N. In vivo analysis using variants of zebrafish BMPR-IA: range of action and involvement of BMP in ectoderm patterning. Development 126, 181–190 (1999).
Kimelman, D. & Griffin, K. J. Vertebrate mesendoderm induction and patterning. Curr. Opin. Genet. Dev. 10, 350–356 (2000).
Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708–712 (1999).
Zhang, X., Giangreco, L., Broome, H. E., Dargan, C. M. & Swain, S. L. Control of CD4 effector fate: transforming growth factor β1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. Exp. Med. 182, 699–709 (1995).
Genestier, L., Kasibhatla, S., Brunner, T. & Green, D. R. Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med. 189, 231–239 (1999).
Gorelik, L. & Flavell, R. A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171–181 (2000).
Geiser, A. G. et al. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl Acad. Sci. USA 90, 9944–9948 (1993).
Lucas, P. J., Kim, S. J., Melby, S. J. & Gress, R. E. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor βII receptor. J. Exp. Med. 191, 1187–1196 (2000).
Nakao, A. et al. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J. Exp. Med. 192, 151–158 (2000).
Vasquez, N. J., Kaye, J. & Hedrick, S. M. In vivo and in vitro clonal deletion of double-positive thymocytes. J. Exp. Med. 175, 1307–1316 (1992).
Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).
Kullberg, M. C. et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and γ-interferon-dependent mechanism. Infect. Immun. 66, 5157–5166 (1998).
Monteleone, G. et al. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108, 601–609 (2001).
Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599–603 (2001).
Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603–606 (2001).
Nakamura, K., Kitani, A. & Strober, W. Cell contact-dependent Immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629–644 (2001).
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).Initial demonstration of the role of CD25+CD4+ T cells in the regulation of autoimmunity.
Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10, 1969–1980 (1998).
Shevach, E. M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423–449 (2000).
Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455–458 (2000).
Powrie, F., Carlino, J., Leach, M. W., Mauze, S. & Coffman, R. L. A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J. Exp. Med. 183, 2669–2674 (1996).
Thornton, A. M. & Shevach, E. M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296 (1998).
Fadok, V. A. et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405, 85–90 (2000).Cloning of the phosphatidylserine specific receptor and demonstration of its role in the TGF-β production by macrophages in response to apoptotic cells.
Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nature Med. 5, 1249–1255 (1999).
Chen, W., Frank, M. E., Jin, W. & Wahl, S. M. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14, 715–725 (2001).
Heine, U. I. et al. Localization of transforming growth factor-β1 in mitochondria of murine heart and liver. Cell. Regul. 2, 467–477 (1991).
Bogdan, C. & Nathan, C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. N Y Acad. Sci. 685, 713–739 (1993).
Vodovotz, Y. & Bogdan, C. Control of nitric oxide synthase expression by transforming growth factor-β: implications for homeostasis. Prog. Growth Factor Res. 5, 341–351 (1994).
Yamaguchi, Y., Tsumura, H., Miwa, M. & Inaba, K. Contrasting effects of TGF-β1 and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15, 144–153 (1997).
Geissmann, F. et al. TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162, 4567–4575 (1999).
Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255–258 (2001).
Jin, Y. X. et al. TGF-β1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells. J. Autoimmun. 14, 213–220 (2000).
Lee, Y. J. et al. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158, 2065–2075 (1997).
Nandan, D. & Reiner, N. E. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. J. Immunol. 158, 1095–1101 (1997).
Cazac, B. B. & Roes, J. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13, 443–451 (2000).
Pasche, B. Role of transforming growth factor β in cancer. J. Cell. Physiol. 186, 153–168 (2001).
Chakravarthy, D., Green, A. R., Green, V. L., Kerin, M. J. & Speirs, V. Expression and secretion of TGF-β isoforms and expression of TGF-β-receptors I, II and III in normal and neoplastic human breast. Int. J. Oncol. 15, 187–194 (1999).
van Roozendaal, C. E. et al. Transforming growth factor β secretion from primary breast cancer fibroblasts. Mol. Cell. Endocrinol. 111, 1–6 (1995).
Tamada, K. et al. Immunosuppressive activity of cloned natural killer (NK1. 1+) T cells established from murine tumor-infiltrating lymphocytes. J. Immunol. 158, 4846–4854 (1997).
Seo, N., Tokura, Y., Takigawa, M. & Egawa, K. Depletion of IL-10- and TGF-β-producing regulatory γδ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163, 242–249 (1999).
Won, J. et al. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res. 59, 1273–1277 (1999).
Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118–1122 (2001).
Massagué, J. How cells read TGF-β signals. Nature Rev. Mol. Cell Biol. 1, 169–178 (2000).
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
FURTHER INFORMATION
Glossary
- EPIGENETIC
-
Epigenetics is the study of heritable changes in gene expression that occur without a change in DNA sequence.
- T-BOX FAMILY
-
A new family of transcription factors that seems to be crucial in the development of all animal species was recently uncovered on the basis of homology of the DNA-binding domain of the Brachyury, or T locus, gene product.
- GATA FAMILY
-
The members of the Gata family of DNA-binding proteins contribute to the transcriptional regulation of cell-lineage commitment and differentiation. Each recognizes a DNA consensus-sequence motif (T/A)GATA(A/G) through a highly conserved DNA-binding domain comprising two zinc fingers.
- POSITIVE SELECTION
-
The process in the thymus that selects thymocytes expressing T-cell receptors (TCRs) that have the ability to interact weakly with self-MHC.
- INFLAMMATORY BOWEL DISEASE
-
(IBD). A group of conditions, of unknown aetiology, in which the intestinal mucosa is chronically inflammed. Includes Crohn's disease and ulcerative colitis.
- CLASS II TRANSACTIVATOR
-
(CIITA). A non-DNA-binding co-activator that functions as a master control factor for MHC class II expression.
Rights and permissions
About this article
Cite this article
Gorelik, L., Flavell, R. Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2, 46–53 (2002). https://doi.org/10.1038/nri704
Issue Date:
DOI: https://doi.org/10.1038/nri704
This article is cited by
-
The endometrial transcriptome transition preceding receptivity to embryo implantation in mice
BMC Genomics (2023)
-
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy
Molecular Cancer (2022)
-
Novel therapies emerging in oncology to target the TGF-β pathway
Journal of Hematology & Oncology (2021)
-
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
Cell Death Discovery (2021)
-
Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis
Cancer Cell International (2020)